spacer
home > ebr > spring 2019 > a new class of innovation
PUBLICATIONS
European Biopharmaceutical Review

A New Class of Innovation

EBR: What promise do advanced therapy medicinal products (ATMPs) offer in terms of treatment?

ATMPs are a rapidly growing, diverse variety of technologies covering a various range of therapeutic areas. The technologies include:

• Autologous cell therapies: Cells removed from a patient, processed in some way, and returned to the same patient
• Allogeneic cell therapies: Cells capable of being banked and can be administered to multiple patients after processing
Ex vivo gene therapies: Autologous or allogeneic cell therapies which are genetically modified as part of the Good Manufacturing Practice process (to correct a faulty gene or target the cell in a predetermined way to, for example, attack a tumour) prior to being returned to the patient
In vivo gene therapies: Direct injection of a viral or nonviral delivery system which will correct one or more faulty genes in the body

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Angela Osborne is Managing Director at eXmoor Pharma Concepts, which she founded in 2004. Angela has a BSc and PhD in biochemical engineering from University College London, UK, and over 30 years’ experience in biopharmaceutical and cell and gene therapy businesses, processes, and facilities. Her previous roles include Senior Vice President of Pharmaceuticals at Aker Kvaerner and Group Leader of Process Engineering at British Biotech. eXmoor is now a globally recognised biopharmaceutical and cell and gene therapy manufacturing consultancy that has completed more than 300 projects across 12 countries. Angela is also a member of the BioIndustry's Association Cell Therapy Industry Group Advisory Committee and the Manufacturing Advisory Committee as well as the co-founder of the ATMP Manufacturing Community.
spacer
Dr Angela Osborne
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement